BriaCell Therapeutics Corp. (BCTX) Liabilities and Shareholders Equity (2019 - 2026)

BriaCell Therapeutics has reported Liabilities and Shareholders Equity for 8 years, with the latest figure at $27.1 million in Q2 2026.

• Quarterly Liabilities and Shareholders Equity rose 59.23% year-over-year to $27.1 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $95.4 million (up 123.65% YoY) and the FY2025 annual result came in at $21.6 million, up 268.68% from the prior year.
• Liabilities and Shareholders Equity fell to $27.1 million in Q2 2026 per BCTX's latest filing, from $33.6 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $48.6 million in Q1 2022 and troughed at $5.9 million in Q3 2024.
• A 5-year average of $24.6 million and a median of $24.4 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity sank 79.13% in 2024, then jumped 268.68% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $38.5 million in 2022, then slumped by 51.58% to $18.6 million in 2023, then sank by 44.07% to $10.4 million in 2024, then rose by 25.55% to $13.1 million in 2025, then surged by 107.05% to $27.1 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $27.1 million, $33.6 million, and $13.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.